Linaclotide
Linaclotide is a pharmaceutical drug with 26 clinical trials. Currently 2 active trials ongoing. Historical success rate of 95.0%.
Success Metrics
Based on 19 completed trials
Phase Distribution
Phase Distribution
2
Early Stage
5
Mid Stage
15
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
95.0%
19 of 20 finished
5.0%
1 ended early
2
trials recruiting
26
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Linaclotide in Treating Patients With Stages 0-3 Colorectal Cancer
A Study to Assess Adverse Events and Change in Disease Activity in Pediatric Participants (Age 6 Months to <2 Years) With Functional Constipation Who Are Treated With Linaclotide
GCC Agonist Signal in the Small Intestine
A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects, Ages 2 to 5 Years, With Functional Constipation
Linaclotide Safety and Efficacy in Pediatric Participants, 6 to 17 Years of Age, With Irritable Bowel Syndrome With Constipation (IBS-C) or Functional Constipation (FC)
Clinical Trials (26)
Linaclotide in Treating Patients With Stages 0-3 Colorectal Cancer
A Study to Assess Adverse Events and Change in Disease Activity in Pediatric Participants (Age 6 Months to <2 Years) With Functional Constipation Who Are Treated With Linaclotide
GCC Agonist Signal in the Small Intestine
A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects, Ages 2 to 5 Years, With Functional Constipation
Linaclotide Safety and Efficacy in Pediatric Participants, 6 to 17 Years of Age, With Irritable Bowel Syndrome With Constipation (IBS-C) or Functional Constipation (FC)
Post-marketing Surveillance of Linaclotide Tablet in Patients With Irritable Bowel Syndrome With Constipation or Chronic Constipation (Excluding Constipation Due to Organic Diseases)
A Study to Evaluate the Effect of ASP0456 in Patients With Constipation Predominant Irritable Bowel Syndrome
A Study of Oral Dosing of ASP0456 in Patients With Chronic Constipation
Phase III Study to Evaluate the Efficacy and Safety of ASP0456 in Patients With Constipation Predominant Irritable Bowel Syndrome
Linaclotide Safety and Efficacy in 2 to 5-Year-Old Participants With Functional Constipation
Efficacy of Linaclotide in Patients With Overlapping Functional Gastrointestinal Disorders
A Study of the Effect of Linaclotide on Abdominal Girth in Participants With Irritable Bowel Syndrome With Constipation (IBS-C)
Effect and Safety of Polyethylene Glycol Combined With Linaclotide on Colon Cleansing for Patients With Chronic Constipation
Evaluation of Clinical Equivalence Between Two Linaclotide Products in the Treatment of Chronic Idiopathic Constipation
A Lactation Study in Women Who Are Breastfeeding or Pumping and Are Receiving Linaclotide Therapeutically
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)
Trial of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)
An Open-Label, Long-term Study to Assess the Immunogenicity of LINZESS® (Linaclotide) Administered Orally to Adult Participants With Irritable Bowel Syndrome With Constipation or Chronic Idiopathic Constipation
An Open-Label, Long-Term Safety Study of Linaclotide in Patients With Chronic Constipation or Irritable Bowel Syndrome With Constipation
Investigation of Linaclotide's Effect on the Bi-directional Brain and Gut Axis in IBS-C Patients
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 26